Aurinia reports Q3 loss per share $0.16

Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020. 

Company Quote

-0.11 -1.78%
20 Sep 2019